INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been used as an effective treatment against acute leukemia since the 1970s [1] [2] [3] . It is now well established that the efficacy of allo-HSCT is also partly dependent on the anti-leukemic effect derived from the allogeneic cells from the donor graft, also referred to as the graft-versus-leukemia (GVL) effect. The majority of the GVL effect is mediated by donor T cells contained in the allograft [3] , but is also seen following delayed infusion of donor T cells [donor lymphocyte infusion (DLI)], which have the potential of inducing remission of hematopoietic malignancies that has relapsed or persists after allo-HSCT [4] [5] [6] [7] [8] . The desired GVL effect from donor T cells is frequently countered by the adverse effect associated with the allogeneic T-cell response against normal tissue, termed graftversus-host (GVH) response. Further, the potency of the GVL effect is often not enough for complete eradication of malignancy, particularly in the case of lymphoid malignancies [7] [8] [9] . Several methods have attempted to intensify the GVL effects of allo-HSCT while minimizing the effects of GVH in order to lower toxicity and improve the outcome of treatment with varying degrees of success [10] . Genetically engineered T cells expressing receptors to redirect specificity toward antigens expressed on malignant cells have the potential to generate a very specific GVL response.
Chimeric antigen receptors (CARs) are fusion constructs composed of the variable binding domain of a monoclonal antibody with the activation domain of the T-cell receptor, with additional costimulatory domains of T-cell signaling (i.e., CD28, 4-1BB, Ox40), in second and thirdgeneration CARs [11] [12] [13] . CARs allow for the redirection and activation of effector T cells toward any cell surface molecule upon binding by the antibodyderived receptor, and are independent of major histocompatibility complex (MHC) restriction [12, 13] . Arming T cells with a CAR against CD19 has been very successful in recent trials in the treatment of B-cell malignancies [14-17,18 & 
,19
& ,20]. In B-lineage acute lymphoblastic leukemia (ALL), remission rates of heavily pretreated, relapsed/ refractory patients reach as high as 70-90% after anti-CD19 CART treatment [17,18 & ,19 & ]. A significant proportion of patients receiving CAR T-cell therapy have received an allo-HSCT, thus for CAR treatment, the T cells collected for CAR T-cell production are derived from the allograft. Despite this, graft-versus-host disease (GVHD) has not been observed in the patients following CAR infusion, perhaps because the cells have been tolerized to the transplant recipient prior to collection. Despite the lack of GVHD present in the allo-HSCT recipients, the responses of post-allo-HSCT patients appear to be inferior to those in patients receiving autologous CAR T cells [18 & ]. The discrepancy in response may be attributed to the quantitatively lower or qualitatively inferior lymphocytes at the time of collection resulting from prior chemotherapy regimens, or the qualitative defects of reconstituted allogeneic T cells in the recipient, or both [21] [22] [23] . A potential opportunity associated with the allo-HSCT platform is the potential to use 'healthy' T cells collected from the donor.
Although CAR T cells are often described as having redirected specificity through the CAR receptor (i.e., toward CD19), with the presence of the endogenous T-cell receptor (TCR), it is perhaps more appropriately described as additional specificity. Following allo-HSCT, the precursor frequency of T cells specific for allogeneic antigen (i.e., tumor antigens, normal antigen, viral antigens) has the potential to be relatively high, particularly if donorderived T cells are used as these T cells will not have been tolerized in the recipient. In the presence of both TCR and CAR antigens presented to the CAR T cell, it is not known which receptor will be dominant and how signaling through the endogenous TCR affects the efficacy of the genetically engineered CAR receptor function. Further, there is the possibility of a bystander effect in which the alloreactive T cells may affect the function of T cells that do not possess specificity for allo-antigens [24, 25] but do express the CAR. Thus, the use of allogeneic CAR T cells, particularly healthy donor-derived CAR T cells, requires an understanding of CAR T-cell function in the allogeneic setting.
DONOR-DERIVED CARS IN THE CLINIC
Human CAR T cells are known to cause xenogeneic GVHD in immunocompromised mice [26, 27] . Preclinical experiments, however, suggest that the use of donor-derived allogeneic CAR T cells in immunocompetent mouse models is well tolerated, as demonstrated by low GVHD rates [28] . Currently, there is a paucity of clinical reports in the literature addressing the risks of GVHD and the activity of donor-derived CAR T cells. Kochenderfer et al. had reported a small cohort of patients receiving donorderived CD19-CAR T cells for relapsed hematologic malignancies following allo-HSCT. All patients had at least one prior DLI, with either no GVHD, grade 1 acute GVHD, or mild chronic GVHD. There was no GVHD following donor-derived CD19 CAR T cells in this cohort; however, only 3 of 10 patients responded to the CAR T cells [29 && ]. Of note, patients on this trial did not receive lymphodepleting agents prior to CAR infusion, which is known to be significant for efficacy of adoptive T-cell immunotherapy although data on the importance of lymphodepleting therapy in the context CAR T cells are lacking. Nonetheless, it is difficult to draw conclusions regarding efficacy in this small series as all autologous CAR reports incorporate lymphodepletion prior to infusion.
A second report of donor-derived allogeneic CAR T therapy utilized virus-specific T cells (VST) to reduce the risk of GVHD. VSTs are selected by exvivo antigen-driven expansion of T cells and have been used post allo-HSCT for treatment of viralinduced complications [30] [31] [32] [33] . VSTs have been described as a suitable backbone for different CAR
KEY POINTS
No reported GVHD with the use of donor-derived CAR T cells in patients following allo-HSCT.
TCR stimulation confers enhanced expansion of CAR T cells based on viral-specific T cells, in vitro and in clinical trials.
TCR activation could be eliminated with ZFN, transcription activator-like effector nucleases, or CRISPR/CAS9 technology, with potential consequences on CAR functionality.
T cells (for CD30, GD2, CD19, etc.), with an endogenous TCR specific to viral antigens and additional specificity through the CAR receptor against the tumor target [30, [34] [35] [36] [37] . The use of donor-derived CD19 CAR VST was reported in a limited number of patients with no GVHD or cytokine release syndrome observed [38 && ]. Here, expansion of CAR T cells was seen with viral infection or reactivation, suggesting that TCR activation is able to enhance the expansion of infused CAR T cells. The increased CD19 CAR T-cell expansion, however, did not lead to a decrease in normal or malignant B cell numbers suggesting the possibility of impaired functionality of the CAR T cells when activated through endogenous TCR.
Currently, there are six trials on clinicaltrials.gov evaluating the use of allogeneic donor-derived CAR T cells (June 30, 2015, Table 1 ), with some preliminary data presented in an abstract form. An ongoing trial from the MD Anderson group has treated 12 patients with preemptive DLI of donor-derived Sleeping-Beauty transferred CD19 CAR following allo-HSCT. Three patients, all with ALL, remained alive and in remission [39] .
One difference between using unmanipulated polyclonal donor-derived T cells and VST-CAR T cells is that a substantially smaller percentage of the polyclonal population would be predicted to encounter TCR antigen in an allo-recipient based on the precursor frequency reported for allo-specific TCRs. With the use of VST-CAR T cells, every T cell infused could potentially encounter a TCR and CAR antigen simultaneously in the presence of a viral infection or reactivation. If there was an advantage of one receptor over another, the prediction would be a much more pronounced effect with the use of VST-CAR T cells. VST-CAR T cells seem to benefit from enhanced long-term expansion because of stimulation through TCR by viral antigens as compared with stimulation solely through the CAR [30, 34, 35] , but this expansion does not necessarily correlate with CAR efficacy, suggesting a distraction through activation of the TCR. To further understand the explanation for the suboptimal results with the use of allo-CAR T cells as well as to improve such approaches in the future, there is a need to better understand basic immunobiology of T cells in the allogeneic environment, and the interaction of the CAR and the TCR.
CAR VERSUS T-CELL RECEPTOR: IMMUNOBIOLOGY IN THE ALLOGENEIC RECIPIENT
The density of CAR receptors on the T cells, as well as target antigen density, is important to the functionality of CAR T-cell therapy [40] . CAR density, however, differs between different CAR constructs and varies heavily depending on the method used to genetically modify the T cell to express the CAR, and is not typically measured systematically in most CAR reports. The density of TCR on the T-cell surface has been extensively researched, and found to be about 40 000 molecules on a single normal CD4 þ T cell [41] . Investigators also found that CD8 þ T cells are able to produce cytokines with as little as 500-1000 TCRs on the surface, but low receptor levels affect the potency and lytic activity of the T cell [42] . The efficacy of a CAR T cell has been reported to be co-dependent on the expression level of the CAR receptor and expression level of the target antigen [40] . In the case of a second-generation CD20-CAR T cell, it was found that direct binding of hundreds of target antigens was required to activate lytic capacity and thousands of antigens interactions required before the cytokine production occurred [43] . It is possible that there are more TCRs than CARs on a surface of a given T cell, potentially resulting in a TCR advantage. TCR and CAR interactivity and dynamics are of special importance in the context of allogeneic or VST-CARs, in which the presence of both antigens for a substantial proportion of T cells is likely. The binding specificity of a CAR is typically derived from a monoclonal antibody, and significant discrepancies in affinity and avidity between the CAR or the TCR and a target cell may exist, thus affecting T-cell efficacy mediated by either receptor. The inherently low affinity of most endogenous TCRs that survive thymic selection maintains high potency by allowing for a sufficient 'on/off rate' [44] [45] [46] . There is very little known about the importance of affinity for CAR function. High-affinity binding by the antibody portion may not allow for frequent engagement and disengagement, thus affecting signaling through the CD3z chain. Thus, T cells might prefer signaling through native TCR and confer higher response against TCR antigen than CAR antigen. Indeed, investigators have studied activation thresholds of T cells transduced such that there is similar surface expression of TCR and CAR receptors, demonstrating that TCRs were more active in the presence of low antigen levels than cells transduced with CAR. In fact, in the presence of low antigen density, stimulation through TCR resulted in maximum INFg secretion compared with $50% less secretion by the CAR in the presence of low-density CAR antigen [47] . Again, these differences would be accentuated in the allogeneic environment because of the presence of both TCR and CAR antigens. Dominance of TCR signal could potentially lead to increased GVHD and lowered CAR-mediated GVL, although this has not been observed in the very limited number of patients treated with donor-derived CAR T cells as discussed above. Nonetheless, the interaction between the CAR and the TCR has not been thoroughly studied and will be critical for the optimization of CAR T cells in the clinic.
IMPROVING DONOR-DERIVED CARS THROUGH T-CELL SELECTION
Today, many major pharmaceutical companies are investing in the research and development of CAR T-cell design and manufacturing. Ideally, a universal, off-the-shelf, product would offset the costs of individual cell preparation required in trials today [48] . These products would likely be analogous to the donor-derived CAR T cells currently being given after allo-HSCT in limited numbers of ongoing trials. A goal of generating off-the-shelf products would be to potentially administer these without the requirement for a prior HSCT from the same donor. To achieve this, methods for minimizing the potential for donor cell rejection by the recipient and for reducing the allo-reactive potential of the product are needed. The safety and efficacy of such off-the-shelf products remains to be systematically tested. Several approaches have been proposed to increase the efficacy of donor-derived allogeneic CAR T cells with the intention of developing general produced cell products available to patients not qualified for autologous infusions because of challenges such as low lymphocyte numbers or poor lymphocyte quality (and expansion in vitro).
A primary goal of using virus-specific T cells for CAR production is the selection of a T-cell product that does not contain an alloreactive TCR. An additional advantage of CAR products with a virus-specific TCR is the ability to utilize enhanced expansion of the T cells by stimulation through the native TCR using a vaccine approach (such as the varicella-zoster virus vaccine) following adoptive CAR T-cell transfer [49] . A clinical trial addressing this method is currently open for autologous anti-GD2 CAR T cells (NCT01953900).
Another method to enrich for nonallogeneic T cells is by using antigen-experienced memory T cells for CAR transduction [27, 36] . It would be predicted that the vast majority of the T-cell population with a memory phenotype is likely to have encountered antigens other than allogeneic antigens, and T cells carrying TCRs specific to allogeneic antigens would maintain their naive properties. Thus, selection for memory phenotype cells should enrich for a nonalloreactive repertoire. Indeed, memory T cells have been shown to have less potential to generate GVHD [50] [51] [52] in murine models, in part owing to nonalloreactive TCR enrichment, along with evidence that memory cells are less likely to traffic to GVHD target tissues, such as the gastrointestinal tract. One marker that can distinguish memory from naive T cells is CD45RA. Several preclinical models have selected for CD45RA -CD62L þ CD8 þ central memory T cells [36] or CD45RA -T cells [27] to use for CAR production. Both techniques demonstrated good CAR transduction, in-vitro functionality and invivo effect. In addition, the memory CAR T cells maintained antileukemic ability without causing xenogeneic GVHD, a major survival limitation with the use of immunodeficient mice treated with human T cells [27] . There are currently several clinical trials using central memory T cells for anti-CD19 CAR-based immunotherapy in the autologous setting against non-Hodgkin lymphoma or ALL (NCT02051257, NCT01815749, NCT02146924, NCT2153580, NCT01318317), and another using anti-IL-13Ra2 for glioma (NCT02208362). One trial is evaluating central-memory donor-derived CD19 CAR T cells following allogeneic transplant (NCT 01475058, Table 1 ).
Another source of T cells that could be used for CAR immunotherapy is the gd T cell subset. These T cells recognize antigens that are distinct from the protein-derived peptides that comprise allogeneic antigens recognized by the ab TCR. Thus, gd T cells have less allogeneic potential but have been shown to mediate antitumor responses. Although they consist of a minority of peripheral T cells, a single subtype (vd2) can be expanded in vivo prior to T-cell collection after stimulation with zolendronic acid [53] . The MD Anderson group used a different expansion approach, with polyclonal gd T-cell transduction with CD19 CAR followed by ex-vivo expansion on an antigen-presenting layer expressing the CD19 target. This resulted in expanded polyclonal gd T cells that demonstrated in-vitro and in-vivo effects in murine models, although the efficacy was not as dramatic as ab CAR T cells in immunodeficient mice [54] . Interestingly, T cells derived from induced pluripotent stem cells (originally induced from T cells) transduced with CAR have very similar gene expression to gd T cells, providing general as well as CAR-specific antitumor response [55] . Despite initial enthusiasm, recent discoveries demonstrate potential tumor-promoting effects of IL-17-producing gd T cells [56] . Nonetheless, should methods for efficient selection for the IFNg producing gd T cells be elucidated, this T-cell subset will be a potential candidate for CAR T-cell production.
In addition to T cells, natural killer (NK) cells can be used for the generation of CAR products for immunotherapy. NK cells have been shown to contribute significantly to the GVL effect, especially in haplo-identical MHC mismatched/KIR-mismatched settings [57] [58] [59] . Generally, NK cells are considered to have lower allogenicity compared with T cells; nevertheless, NK-mediated GVHD has been reported [60] . NK-CAR cells have shown preclinical efficacy against a variety of tumor-associated antigens [61] [62] [63] [64] [65] . Major challenges with the use of NK-CAR cells include low persistence inherent to NK cell immunotherapy, and complex intracellular signaling machinery potentially not compatible or optimal when using conventional T-cell activation domains. The use of specific NK cell activation domains such as DAP12 [63, 66] is currently being evaluated in preclinical studies.
IMPROVING DONOR-DERIVED CARS THROUGH GENE EDITING
To develop donor-derived T cells without the effects of TCR activation, CAR T cells with CAR-only specificity have been generated by selectively deleting the endogenous TCR. With current gene editing technologies, the endogenous TCR could be excised through the use of nucleases such as zinc-finger nucleases [67] , transcription activator-like effector nucleases [68,69 & ], and the CRISPR/Cas9 system [70] . The absence of an endogenous TCR eliminates the possibility of GVHD or the potential distraction of TCR receptor signaling. Using the same techniques, MHC class I could be deleted on donorderived, off-the-shelf T cells to avoid rejection of transferred cells [71] . Even though novel gene editing tools may prevent GVHD and rejection, significant potential issues remain to be fully tested. Absence of MHC may elicit an NK response against allogeneic T cells. Also, the functionality of a CAR containing a CD3z domain has been shown to be dependent on its ability to dimerize with the endogenous TCR in order to activate downstream pathways through the interactions with the TCR/ CD3 complex [72,73 & ]. The results of these studies suggest that the efficacy of CAR T-cell activity and persistence could be diminished by eliminating or mutating the endogenous TCR or MHC with the use of nucleases.
Last, adding a suicide gene to the CAR construct may be beneficial in minimizing the risk of GVHD after allogeneic CAR T-cell infusion. Inducible caspase 9 (iC9) is an intrinsic activator of apoptosis that can be transduced into allogeneic T cells that are administered following allo-HSCT and can effectively abrogate GVHD [74, 75] . Preclinical models have shown that activation of the suicide iC9 in CAR therapy rescued mice from xenogeneic GVHD in a CD44v6-CAR model [76] . Ongoing clinical trials have incorporated the iC9 construct into CAR T-cell products to provide a method to eliminate autologous CAR T cells in the event of potential off tumor toxicity (NCT02107963, NCT01822652, NCT02439788).
CONCLUSION
CAR T cells are one of the exciting achievements of current adoptive immunotherapy, with noteworthy clinical successes in treating ALL. Currently, many patients may experience lower efficacy because of general T-cell defects from prior chemotherapy or allo-HSCT. The use of donor-derived cells, especially on route to off-the-shelf T cells, needs to be evaluated. Many current studies address safety questions, with multiple techniques being employed to avoid GVHD. Little is known about TCR/CAR interactions and the effects TCR signaling has on therapy outcome. Better understanding of the immunobiology of CAR and TCR signaling and functionality is required before we determine the benefits or pitfalls of including or deleting the endogenous TCR for CAR therapy. Altogether solving challenges in MHC-matched allogeneic CAR T cells will pave the way for off-the-shelf universal CAR T cells.
